The Short-Term Effects of Risperidone-Induced Hyperprolactinemia on Lipid Metabolism in Drug-Naïve Children and Adolescents
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveaaThe present cross-sectional study was designed to assess the risk of elevated prolactin levels and other hormonal or metabolic changes in children and adolescents taking risperidone. MethodsaaTwenty-five children and adolescents [aged 7–18 years, 12.1±3.3 years (mean±SD); 19 boys and 6 girls] who had been taking risperidone for at least 3 months were enrolled. The following blood parameters were measured: serum levels of prolactin, thyroid hormones, alanine transaminase (ALT), sex hormones, lipids. ResultsaaThe median risperidone dosage was 1.55 mg/day (SD 1.14 mg/day, range 0.25–4.00 mg/day). The prolactin level (33.65± 16.71 ng/mL, range 5.8–68.3 ng/mL) was higher than normal, and was elevated (≥15 ng/mL in male, ≥23.3 ng/mL in female) in about 84% of the patients. The dosage of risperidone was positively correlated with serum prolactin level (r=0.767, p<0.001). The TG/HDL ratio was higher in the group with higher prolactin levels (i.e., ≥30 ng/mL), and hence might be a useful marker of insulin resistance. ConclusionaaIn young patients taking risperidone, a high serum prolactin level may influence lipid metabolism, even when cholesterol levels are within the normal range. Further investigation is needed around this issue. Serum prolactin assessment is recommended for children and adolescents taking risperidone.
Abstract
ObjectiveaaThe present cross-sectional study was designed to assess the risk of elevated prolactin levels and other hormonal or metabolic changes in children and adolescents taking risperidone. MethodsaaTwenty-five children and adolescents [aged 7–18 years, 12.1±3.3 years (mean±SD); 19 boys and 6 girls] who had been taking risperidone for at least 3 months were enrolled. The following blood parameters were measured: serum levels of prolactin, thyroid hormones, alanine transaminase (ALT), sex hormones, lipids. ResultsaaThe median risperidone dosage was 1.55 mg/day (SD 1.14 mg/day, range 0.25–4.00 mg/day). The prolactin level (33.65± 16.71 ng/mL, range 5.8–68.3 ng/mL) was higher than normal, and was elevated (≥15 ng/mL in male, ≥23.3 ng/mL in female) in about 84% of the patients. The dosage of risperidone was positively correlated with serum prolactin level (r=0.767, p<0.001). The TG/HDL ratio was higher in the group with higher prolactin levels (i.e., ≥30 ng/mL), and hence might be a useful marker of insulin resistance. ConclusionaaIn young patients taking risperidone, a high serum prolactin level may influence lipid metabolism, even when cholesterol levels are within the normal range. Further investigation is needed around this issue. Serum prolactin assessment is recommended for children and adolescents taking risperidone.
참고문헌 (28)
- Ben-Jonathan N, "Focus on prolactin as a metabolic hormone", Trends Endocrinol Metab, 17, pp.110~116 (2006)
- Landgraf R, "Prolactin: a diabetogenic hormone", Diabetologia, 13, pp.99~104 (1977)
- Johnston DG, "Hyperinsulinaemia in hyperprolactinaemic women", Clin Endocrinol (Oxf), 13, pp.361~368 (1980)
- Fan X, "Triglyceride", high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia, 2011, pp.72, 806~812
- Melkersson K, "Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses", Neuro Endocrinol Lett, 32, pp.428~436 (2011)
- Sikich L, "A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial", Neuropsychopharmacology, 29, pp.133~145 (2004)
- Schur SB, "Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review", J Am Acad Child Adolesc Psychiatry, 42, pp.132~144 (2003)
- Bushe C, "A review of the association between antipsychotic use and hyperprolactinaemia", J Psychopharmacol, 22(2 Suppl), pp.46~55 (2008)
- Cookson J, "Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis", J Psychopharmacol, 26(5 Suppl), pp.42~51 (2012)
- Milano W, "Recent clinical aspects of hyperprolactinemia induced by antipsychotics", Rev Recent Clin Trials, 6, pp.52~63 (2011)
- Staller J, "The effect of long-term antipsychotic treatment on prolactin", J Child Adolesc Psychopharmacol, 16, pp.317~326 (2006)
- Stevens JR, "Elevated prolactin levels in male youths treated with risperidone and quetiapine", J Child Adolesc Psychopharmacol, 15, pp.893~900 (2005)
- Saito E, "Malhotra AK, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents", J Child Adolesc Psychopharmacol, 14, pp.350~358 (2004)
- Johnsen E, "Antipsychotic-induced hyperprolactinemia: a cross-sectional survey", J Clin Psychopharmacol, 28, pp.686~690 (2008)
- Colao A, "Growth-hormone and prolactin excess", Lancet, 352, pp.1455~1461 (1998)
- Findling RL, "Prolactin levels during long-term risperidone treatment in children and adolescents", J Clin Psychiatry, 64, pp.1362~1369 (2003)
- Colao A, "Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization", Clin Endocrinol (Oxf), 52, pp.319~327 (2000)
- Roke Y, "Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects", J Child Adolesc Psychopharmacol, 19, pp.403~414 (2009)
- Alfaro CL, "Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine", J Child Adolesc Psychopharmacol, 12, pp.83~91 (2002)
- Xiang SK, "Relationship between serum lipoprotein ratios and insulin resistance in polycystic ovary syndrome", Int J Endocrinol, 2012, pp.173281~ (2012)
- Luby J, "Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy", J Child Adolesc Psychopharmacol, 16, pp.575~587 (2006)
- Haddad PM, "Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management", wDrugs, 64, pp.2291~2314 (2004)
- Roke Y, "Antipsychotic-induced hyperprolactinemia and testosterone levels in boys", Horm Res Paediatr, 77, pp.235~240 (2012)
- Kaneda Y, "Effects of risperidone on gonadal axis hormones in schizophrenia", Ann Pharmacother, 35, pp.1523~1527 (2001)
- Kaneda Y, "Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation", Int J Neuropsychopharmacol, 6, pp.247~252 (2003)
- Dunbar F, "Growth and sexual maturation during long-term treatment with risperidone", Am J Psychiatry, 161, pp.918~920 (2004)
- Markianos M, "Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone", Psychopharmacology (Berl), 143, pp.270~272 (1999)
- Konarzewska B, "Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia", Psychoneuroendocrinology, 34, pp.129~139 (2009)